Novo Nordisk sinks after Ozempic’s key ingredient fails to slow down Alzheimer’s in trials
Novo Nordisk is down nearly 9% in trading in Europe, with its US-listed ADRs dropping a similar amount, after the pharma giant shared that oral semaglutide — a key ingedient behind its Ozempic and Wegovy drugs — didn’t slow Alzheimer’s disease in two trials.
Per the company’s press release, oral semaglutide failed to show a statistically significant reduction in early-stage Alzheimer’s disease progression compared to a placebo across two large-scale, late-stage trials. From the release:
The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care.
Treatment with semaglutide did result in improvement of some Alzheimer’s disease-related biomarkers, but it “did not translate into a delay of disease progression.”
Noting that the trials were conducted “despite a low likelihood of success” from the start, chief scientific officer Martin Holst Lange commented that, “while semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer’s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities.”